Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

97 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.
Johnson M, Grinsztejn B, Rodriguez C, Coco J, DeJesus E, Lazzarin A, Lichtenstein K, Rightmire A, Sankoh S, Wilber R. Johnson M, et al. Among authors: wilber r. AIDS. 2005 Jan 28;19(2):153-62. doi: 10.1097/00002030-200501280-00007. AIDS. 2005. Corrected and republished in: AIDS. 2005 Apr 29;19(7):685-94. doi: 10.1097/01.aids.0000166091.39317.99 PMID: 15668540 Corrected and republished. No abstract available.
Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir.
Leung N, Peng CY, Hann HW, Sollano J, Lao-Tan J, Hsu CW, Lesmana L, Yuen MF, Jeffers L, Sherman M, Min A, Mencarini K, Diva U, Cross A, Wilber R, Lopez-Talavera J. Leung N, et al. Among authors: wilber r. Hepatology. 2009 Jan;49(1):72-9. doi: 10.1002/hep.22658. Hepatology. 2009. PMID: 19065670 Clinical Trial.
Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.
Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, DeHertogh D, Wilber R, Zink RC, Cross A, Colonno R, Fernandes L; BEHoLD AI463027 Study Group. Lai CL, et al. Among authors: wilber r. N Engl J Med. 2006 Mar 9;354(10):1011-20. doi: 10.1056/NEJMoa051287. N Engl J Med. 2006. PMID: 16525138 Free article. Clinical Trial.
A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.
Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, Lok AS, Han KH, Goodman Z, Zhu J, Cross A, DeHertogh D, Wilber R, Colonno R, Apelian D; BEHoLD AI463022 Study Group. Chang TT, et al. Among authors: wilber r. N Engl J Med. 2006 Mar 9;354(10):1001-10. doi: 10.1056/NEJMoa051285. N Engl J Med. 2006. PMID: 16525137 Free article. Clinical Trial.
Phase I study of multiple-dose cefprozil and comparison with cefaclor.
Barbhaiya RH, Shukla UA, Gleason CR, Shyu WC, Wilber RB, Martin RR, Pittman KA. Barbhaiya RH, et al. Among authors: wilber rb. Antimicrob Agents Chemother. 1990 Jun;34(6):1198-203. doi: 10.1128/AAC.34.6.1198. Antimicrob Agents Chemother. 1990. PMID: 2393281 Free PMC article. Clinical Trial.
Excretion of cefprozil into human breast milk.
Shyu WC, Shah VR, Campbell DA, Venitz J, Jaganathan V, Pittman KA, Wilber RB, Barbhaiya RH. Shyu WC, et al. Among authors: wilber rb. Antimicrob Agents Chemother. 1992 May;36(5):938-41. doi: 10.1128/AAC.36.5.938. Antimicrob Agents Chemother. 1992. PMID: 1510416 Free PMC article.
Effect of antacid on the bioavailability of cefprozil.
Shyu WC, Wilber RB, Pittman KA, Barbhaiya RH. Shyu WC, et al. Among authors: wilber rb. Antimicrob Agents Chemother. 1992 May;36(5):962-5. doi: 10.1128/AAC.36.5.962. Antimicrob Agents Chemother. 1992. PMID: 1510420 Free PMC article.
97 results